DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

Post-LOE

dorzolamide hydrochloride and timolol maleate

Novartis

ANDAOPHTHALMICSOLUTION/DROPS

Approved

May 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE (dorzolamide hydrochloride and timolol maleate) by Novartis is components: dorzolamide hydrochloride and timolol maleate. Approved for elevated intraocular pressure (iop) in patients with open-angle glaucoma, ocular hypertension, hypertension and 1 more indications. First approved in 2020.

Drug data last refreshed 18h ago

Mechanism of Action

components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve…

Indications (4)

elevated intraocular pressure (IOP) in patients with open-angle glaucoma

Worked on DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.